Objective: Pregnancy and lactation-associated osteoporosis (PLO) is a rare disease, which can lead to vertebral fractures in women of reproductive age. No treatment strategy for PLO has been established. Here we report a case of PLO treated with teriparatide followed by denosumab, in which remarkable improvement in bone mineral density (BMD) was achieved.
Case Report: A 27-year-old woman experienced severe back pain two weeks after her first delivery. PLO was diagnosed from her low BMD and multiple vertebral compression fractures. She was treated with teriparatide for 6 months, followed by denosumab. After 1 year, her BMD increase from baseline was 16.5% in L2∼4 and her pain had been relieved.
Conclusion: In addition to weaning, administration of teriparatide followed by denosumab led to remarkable improvement in the patient's symptoms and BMD. Therefore, we regard this method as a promising choice for the treatment of PLO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tjog.2017.10.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic kidney disease (CKD) has shown a growing association with osteoporosis, comprising part of the broader CKD-mineral and bone disorder (CKD-MBD). CKD-MBD is marked by alterations in calcium, phosphorus, parathyroid hormone (PTH), and vitamin D metabolism, significantly elevating fracture risk. While traditional osteoporosis treatments such as bisphosphonates, denosumab, and teriparatide have been adapted for CKD patients, recent innovations have introduced agents aimed at enhancing bone mass and reducing fracture incidence.
View Article and Find Full Text PDFSurgical Management of Adult Spinal Deformity Patients with Osteoporosis.
J Clin Med
November 2024
Department of Orthopedic Surgery, The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
Adult spinal deformity (ASD) commonly affects older adults, with up to 68% prevalence in those over 60, and is often complicated by osteoporosis, which reduces bone mineral density (BMD) and increases surgical risks. Osteoporotic patients undergoing ASD surgery face higher risks of complications like hardware failure, pseudoarthrosis, and proximal junctional kyphosis (PJK). Medical management with antiresorptive medications (e.
View Article and Find Full Text PDFVerifying the effectiveness of romosozumab re-administration on bone mineral density.
J Bone Miner Res
December 2024
Department of Orthopedic Surgery, Division of Osteoporosis, Locomotive Syndrome, Joint Disease Center, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.
Upon completing romosozumab therapy for osteoporosis, sequential treatment with other agents is required. However, for patients at high fracture risk despite such therapy, re-administration of romosozumab might be a potent option for subsequent medication to prevent additional fractures. Currently, there is still insufficient real-world clinical data verifying the efficacy of romosozumab re-administration, therefore, this study aimed to evaluate its efficacy.
View Article and Find Full Text PDFPregnancy- and Lactation-Associated Osteoporosis: A Literature Review Based on a Clinical Case.
Cureus
November 2024
Orthopedics and Traumatology, Santo António University Hospital Center, Porto, PRT.
Article Synopsis
- Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition impacting women postpartum, exemplified by a case of a 29-year-old with severe back pain due to vertebral fractures.
- Diagnosis involves ruling out other causes of osteoporosis, with treatment typically including calcium and vitamin D supplements alongside lactation suppression; however, pain may persist even after treatment.
- The condition remains poorly understood, with potential causes including genetic factors and calcium metabolism changes, highlighting the need for early diagnosis and personalized treatment strategies for better patient outcomes.
Correction: Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
Arch Osteoporos
November 2024
College of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!